Chemotherapy sensitivity and outcomes in breast cancer are influenced by various factors, including hormone receptor (HR) status, human epidermal growth factor receptor 2 (HER2) expression, Ki-67 index, lymphovascular invasion, tumor stage, histological grade, and molecular classification3. This evidence concerns the gene ERBB2 and breast cancer.